Eli Lilly (LLY)
(Delayed Data from NYSE)
$807.43 USD
-1.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $808.30 +0.87 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 401 - 420 ( 428 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Third Quarter Revenue Increased 9% but Heavy Spending Led to Lower Earnings
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Raising our CY11 estimates in view of strong performance in Q2 CY11, though concern remains
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Positive volume Growth with Favorable Currency Trends
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Delays and setbacks on R&D front add further to existing concerns over earnings growth & pipeline productivity.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
First Quarter Results Benefit from Strong International Sales
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
EPS for 2010 Up 7%. Acquisition Dilution and Patent Expirations Could Lower 2011 Earnings.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Recent setbacks on R&D front add further to concerns over growth & pipeline productivity.....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Exceeded Expectations. Focus Shifts to Development Pipeline.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Pipeline still remains too early-stage to meaningfully offset revenue loss arising from patent expiry
Provider: FIRST GLOBAL
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Increased Volume Contributed to Double-Digit Second Quarter EPS Growth. Estimates Raised.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S